Miranda R. Cai

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials”.

Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials

Vaccine(2023)10.1016/j.vaccine.2023.05.016

N/A

0DataRank · unranked

11 citations

Karim Hegazy, Miranda R. Cai, Irene McKnight, Matthew D. Rousculp, Katia Alves +1 more

Safety of the NVX-CoV2373 COVID-19 Vaccine in Randomized Placebo-Controlled Clinical Trials

medRxiv(2023)10.1101/2023.02.24.23285601

N/A

0DataRank · unranked

1 citations

Karim Hegazy, Miranda R. Cai, Irene McKnight, Matthew D. Rousculp, Katia Alves +1 more

Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19)

Vaccine(2025)10.1016/j.vaccine.2025.127362

N/A

0DataRank · unranked

3 citations

Alice McGarry, Wayne Woo, Karen L. Kotloff, Cynthia L. Gay, Mingzhu Zhu +15 more